| |
|
|
DURHAM, N.C. - Merix Bioscience Inc. has allocated $39.5 million of private financing to complete a 20,000-sf cell processing facility that will support the company's progress into Phase I clinical trials for its cancer vaccine.
|
|
 |
Would you like information like this delivered to your email inbox? Subscribe to Tradeline Updates to keep abreast of the latest conference developments, industry news, best practices and more! Sign Up Now!
|
|
Printer Friendly Version
Send to a Friend
